4月5日,安进(AMGN)盘中下跌5.06%,截至03:53,报294.16美元/股,成交11.36亿美元,总市值1580.24亿美元。
财务数据显示,截至2024年12月31日,安进收入总额334.24亿美元,同比增长18.57%;归母净利润40.9亿美元,同比减少39.11%。
大事提醒:
5月1日,安进将披露2025财年一季报(数据来源于纳斯达克官网,预计披露日期为美国当地时间,实际披露日期以公司公告为准)。
资料显示,安进公司主要从事人用创新药物的探索、研发、生产和销售,致力于发掘生物科技潜力以用于对患有严重疾病患者的治疗。
安进关注的是未满足的医疗需求领域,并利用其专业知识,努力寻求改善健康状况并显著改善人们生活的解决方案。作为生物技术的先驱,安进已经成长为世界领先的独立生物技术公司之一,已经在世界范围内治疗了数百万的病人。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.